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ABSTRACT
Aberrant activation of RAS/MAPK signaling is a
driver of over one third of all human carcinomas. The
homologous transcription factors ETS1 and ETS2
mediate activation of gene expression programs
downstream of RAS/MAPK signaling. ETS1 is im-
portant for oncogenesis in many tumor types. How-
ever, ETS2 can act as an oncogene in some cellular
backgrounds, and as a tumor suppressor in others,
and the molecular mechanism responsible for this
cell-type specific function remains unknown. Here,
we show that ETS1 and ETS2 can regulate a cell mi-
gration gene expression program in opposite direc-
tions, and provide the first comparison of the ETS1
and ETS2 cistromes. This genomic data and an ETS1
deletion line reveal that the opposite function of ETS2
is a result of binding site competition and transcrip-
tional attenuation due to weaker transcriptional acti-
vation by ETS2 compared to ETS1. This weaker ac-
tivation was mapped to the ETS2 N-terminus and a
specific interaction with the co-repressor ZMYND11
(BS69). Furthermore, ZMYND11 expression levels in
patient tumors correlated with oncogenic versus tu-
mor suppressive roles of ETS2. Therefore, these data
indicate a novel and specific mechanism allowing
ETS2 to switch between oncogenic and tumor sup-
pressive functions in a cell-type specific manner.
INTRODUCTION
Mutations activating the RAS/RAF/MEK/ERK
(RAS/MAPK) signaling pathway are among the most
common drivers of carcinogenesis (1). Activation of this
pathway leads to phosphorylation and activation of ERK,
which can translocate into the nucleus and phosphory-
late a variety of transcription factors leading to altered
gene expression (2). These ERK-induced gene expression
changes promote oncogenic phenotypes such as increased
proliferation, resistance to apoptosis and increased cell
migration and invasion (3). Therefore, the transcription
factors that mediate the function of the RAS/MAPK
pathway represent an important class of therapeutic
targets.
The homologous transcription factors, ETS1 and ETS2,
are critical nuclear effectors of the RAS/MAPK cascade
(4–6). These two proteins are ubiquitously expressed, how-
ever relative levels can vary substantially between cell types
(7). ETS1 and ETS2 and share 55% amino acid similar-
ity (8). ETS1 and ETS2 both have an ETS DNA binding
domain, pointed domain, and ERK and CAMKII phos-
phorylation sites (9,10). The pointed domain facilitates in-
teractions between ETS1 or ETS2 and the co-activator
CBP/p300. Phosphorylation of a threonine neighboring the
pointed domain (ETS1 T38/ETS2 T72) by ERK increases
affinity of ETS1 and ETS2 for CBP/p300, leading to in-
creased activation of RAS/MAPK target genes (11).
Genetic and biochemical studies demonstratemany func-
tional redundancies between ETS1 and ETS2 during early
development, cell survival, cell proliferation and oncogene-
sis (12,13). ETS1 and ETS2 have identical consensus in vitro
DNA sequence preferences (14). Mice with a homozygous
knockout of ETS1 are viable in some genetic backgrounds
(15,16), as are mice where the wild-type (WT) version of
ETS2 has been replaced with the phospho-null ETS2 T72A
mutation (17). However, homozygous loss of ETS1 in mice
coupled with a homozygous ETS2 T72A mutation results
in lethality, indicating a redundant function that requires
ERK phosphorylation (12). In Head and Neck Squamous
Cell Carcinoma (HNSCC), ETS1 and ETS2 both function
as drivers of oncogenesis. Elevated expression of both fac-
tors is observed in HNSCC tumors compared to normal
mucosa and this results in increased expression of onco-
genes such asCIP2A (18),CXCL1/2 (19) andVimentin (20).
Likewise, expression levels of both ETS1 and ETS2 corre-
late with higher histological grading and poorer outcomes
of ovarian and endometrial cancers (21,22).
Despite evidence of redundant functions in many sys-
tems, there are reports of ETS1 and ETS2 having opposite
functions. One example is the ability for ETS1 to repress B-
cell differentiation through activation of the BLIMP1 gene,
while ETS2 cannot activateBLIMP1 expression (23). In tu-
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mors, ETS1 appears to function consistently as an oncogene
(24), however ETS2 is often reported to be a tumor sup-
pressor (25). An extra copy of ETS2 present in mice har-
boring Trisomy XXI conferred resistance to the formation
of solid tumors driven by APC(Min) (26). In non-small cell
lung cancers, ETS2 expression functions to inhibit expres-
sion of theMET oncogene and weakens RAS/MAPK sig-
naling intensity (27). Recently, it has been shown that the
loss of one copy of ETS2 that occurs during TMPRSS2-
ERG gene rearrangements in prostate cancer leads to more
aggressive prostate tumors and poor survival outcome (28).
We recently described a critical role for ETS1 as an effec-
tor of RAS/MAPK signaling in cancer cell lines containing
mutant KRAS, however, we found that ETS2 has the op-
posite function (6). Taken together, these findings indicate
an oncogenic role for ETS1, but a role for ETS2 that can
be either oncogenic or tumor suppressive depending on the
cellular background. However, the molecular mechanisms
that allow ETS2 to function as a tumor suppressor are un-
known.
Here, we report that ETS1 and ETS2 divergently regu-
late a common cell migration gene expression program in
prostate cancer cells. Mapping the ETS2 cistrome showed
that it binds to the same regions as ETS1. These regions
have ETS/AP1 binding sequences and occur near genes
involved in cell migration. ETS2 reduced gene expression
in the presence of ETS1, but activated in the absence of
ETS1 supporting a competition model where ETS2 acts as
a weaker activator than ETS1. Using a panel of chimeric
ETS1/2 constructs we demonstrate that the N-terminal
region of ETS2 reduces activation compared to ETS1,
and this region specifically interacts with the co-repressor
ZMYND11. Binding of ZMYND11 to ETS1/2 co-bound
regions increased in the ETS1 knockout, consistent with
binding site competition. Knockdown of ZMYND11 in the
ETS1 knockout rescued the cell migration phenotype in-
dicating that this molecule is key to attenuation by ETS2.
High expression of ZMYND11 predicted improved recur-
rence free survival in patients with prostate cancer. Fi-
nally, high ZMYND11 expression levels in tumors cor-
relate with a tumor suppressive function of ETS2 across
many epithelial tumors. Together, these data indicate that
the ZMYND11 interaction is a specific mechanism for the
cell type dependent tumor suppressive function of ETS2.
MATERIALS AND METHODS
Cell culture and viral transduction
Cell lines were cultured by ATCC recommendation as fol-
lows: EBNA293, HEK-293T, DU145 were grown in Dul-
becco’s modification Eagle (DMEM) [Sigma] with 10% fe-
tal bovine serum (FBS) [Sigma]. A549 cells were grown in
F12K (Sigma) with 10% FBS [Sigma]. All media included
1× Penicillin/Streptomycin (Mediatech-Cellgro).
Lentivirus for ETS factor shRNA was produced by
co-transfection of pLKO.1 (Addgene plasmid 8453) (29)
with shRNA sequences (Supplementary Table S1) in
HEK293T cells with pMDLg/pRRE (Addgene plasmid
12251), pRSV-Rev (Addgene plasmid 12253) and pMD2.G
(Addgene plasmid 12259) packaging plasmids (30) as pre-
viously described (31).
RNA sequencing and analysis
Total RNA for three independent biological replicates
was isolated from DU145 cells transduced with lentiviral
shRNA knockdown vectors (see above) using the RNeasy
mini kit (Qiagen) according to manufacturer’s instructions.
Sequencing libraries for whole transcriptome analysis were
generated by Illumina TruSeq sample preparation proto-
col. Number of mapped reads as determined by Samtools
from TopHat output is found in Supplementary Table S2
and clustering of RNA-seq replicates can be found in Sup-
plementary Figure S1A.
Data files are available for download from NCBI’s Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/
geo/), accession number GSE59020 (ETS1 shRNA) or
GSE86240 (ETS2 shRNA).
Generation of ETS1 knockout cell lines
ETS1 knockout lines were generated using the D10A Cas9
Nickase, pX335-U6-Chimeric BB-CBh-hSpCas9n(D10A)
(Zhang, Addgene #42235). Guide RNA’s (gRNA) were
generated using algorithms found at crispr.mit.edu (Supple-
mentary Table S1). gRNA’s were cloned into the Cas9 back-
bone as described previously (32) and 5 g of each gRNA
was transfected into DU145 cells. Puromycin (5mg/mL)
was added at 24 h, and washed out at 48 h. Transfected cells
were counted and diluted to a concentration of 1 cell/200
l. In a 96-well plate, 100 l of diluted cells were plated
and allowed to grow to confluence. Single colonies were
tested for knockout via protein immunoblotting (described
below). CRISPR/Cas9 generated indels were identified via
gDNA PCR and sequencing of individual clones.
Protein immunoblotting and RNA quantification
Total protein extract from equal number of cells were sepa-
rated on 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis gels, transferred to nitrocellulosemembrane
(Bio-Rad), blocked in 5% milk in TBS (10 mM Tris, pH8.0,
150 mMNaCl), incubated with primary and secondary an-
tibodies and visualized by ECL (Thermo Scientific) using
standard procedures. Antibodies were the same as for ChIP
plus anti-FLAG (Sigma) and anti-Tubulin (Sigma).
RNA levels were measured by reverse transcription fol-
lowed by quantitative RT-PCR with standard curves as de-
scribed previously (7) using DNA oligonucleotides in Sup-
plementary Table S1. RNA levels were normalized to 18S
rRNA.
Transwell migration assays
Transwell migration assays were carried out as previously
described (33), with minor modifications. In brief, 1 × 105
cells were introduced to the transwell (8 M pore size;
BD Bioscience) and incubated 24 h. Cells containing over-
expression vectors were transiently transfected using Tran-
sit2020 (Mirus) 24 h prior to performing migration assay.
Each experiment is three biological replicates containing the
mean of two technical replicates.
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Chromatin immunoprecipitation and sequencing
ChIP was carried out as previously described (33). In short,
cells were crosslinked using 1% v/v Formaldehyde (Fisher
Scientific) for 15 min and quenched with 2M Glycine for 5
min. Isolated cells were lysed and sonicated for 3 min (30 s
ON/OFF) [Daigenode, Bioruptor Pico]. Nuclear lysate was
rotated with speciifc antibody for 4 h at 4◦C, washed, and
DNA isolated by phenol/chloroform. ChIP antibodies used
were from Santa Cruz Biotechnology: the dual specificity
ETS1/ETS2 antibody was x-ETS2 (sc-351, lot #H2115),
the ETS1 specific antibody was ETS1 (sc-350, lot #F1312)
and ZMYND11 (sc-292571, lot #K1814). Library prepara-
tionwas carried out as previously described (6). Peak calling
and downstream analysis including intersect regions used
theUSeq platform (http://useq.sourceforge.net/). Cross cor-
relation analysis (NSC/RSC values) is in Supplemental Ta-
ble S3.
ChIP-seq Data files generated in this study can be found
via Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) accession number GSE86240. Data sets reana-
lyzed were obtained via accession number GSE59021 (6).
Motif searching and ontology analysis
Enriched motif searching was accomplished using the
RSAT ‘peak motifs’ platform (http://rsat.sb-roscoff.fr/).
Settings for motif enrichment using RSAT are as followed:
Discover over-represented words and discover words with
local over-representation at an oligomer length of 6, 7
and 8. Number of motifs returned per algorithm was set
equal to 5. All other options remained as default set-
tings. Ontology searches were done using g:Profiler (http:
//biit.cs.ut.ee/gprofiler/). Settings for g:Profiler ontology al-
gorithm are as followed: output style––textual, max func-
tional category––1500, significant only. All other settings
remained default. Significance is shown as corrected P-
value.
Pull down and co-immunoprecipitation assays
His-tagged purified ETS (34) were diluted in 300 l
binding/wash buffer (100 mM Sodium phosphate pH 8.0,
600 mM NaCl and 0.02% Tween 20) and incubated with
2.5 l of His-tag Dynabeads (Life Technologies) for 2 h in
a rocker. Unbound ETS proteins were removed by wash-
ing the beads two times with binding/wash buffer. With the
bead bound ETS proteins, ∼14 g of PC3 nuclear extracts
(sc-2152, Santa Cruz Biotechnology) along with 100 g of
BSA were rotated for 1–2 h. Beads were washed four times
with NP-40 lysis buffer and proteins eluted using sodium
dodecyl sulphate (SDS) protein loading dye. Eluted proteins
were separated in a SDS gel and transferred to a nitrocellu-
losemembrane, whichwas Ponceau stained (0.1 in 5%acetic
acid) and immunoblotted.
For co-immunoprecipitation, whole-cell extracts were
isolated from DU145 cells using cell lysis buffer (50 mM
Hepes-KOH pH 8.0, 140 mMNaCl, 1 mMEDTA, 0.5 mM
EGTA, 10% glycerol, 0.5% Nonidet p40, 0.25% Triton X-
100). Indicated antibodies were added to supernatants and
rotated overnight in a rocker at 4C. 50 l of respective Dyn-
abeads (Invitrogen) were then added and rotated for 4 h in
Figure 1. ETS1 and ETS2 divergently regulate a cell migration gene ex-
pression program. (A) Representative immunoblot of DU145 cells stably
expressing ETS1, ETS2, or, as a control, luciferase (luc.) shRNA. Anti-
tubulin blot is a loading control. Image J quantification of three indepen-
dent biological replicates relative to the luciferase shRNA is shown asmean
and SEMunder each lane. (B) Dot plot of differential gene expression from
triplicate RNA-sequencing of DU145 cells with control shRNA compared
to DU145 with ETS1 or ETS2 shRNA. Only direct ETS1 target genes in
DU145 as determined by ChIP-seq (6) are shown. Number in each quad-
rant indicates the quantity of genes with expression changes of log2 > 0.2
in both the ETS1 shRNA and ETS2 shRNA clones. (C) Gene ontology
analysis of 337 genes activated by ETS1 but repressed by ETS2 expression
ranked by –log10P-value.
a rocker. Beads were washed four times with NP-40 lysis
buffer and immunoblotted.
TCGA data curation and Kaplan–Meier curve analysis
RNA-sequencing analysis of patient tumor data curated by
the TCGA consortium (35) was analyzed usingUCSCCan-
cer Browser (https://genome-cancer.ucsc.edu). Relevant
survival data was downloaded and Kaplan-Meier curve
analysis, along withP-value generation were analyzed using
the ‘Survival’ library within the R suite as described at the
package website (https://cran.r-project.org/web/packages/
survival/index.html). For ZMYND11/ZMYND11 expres-
sion analysis across tumors, expression data was down-
loaded from cBioPortal (http://www.cbioportal.org/) and
reconstituting using Prism analysis software.
RESULTS
ETS1 and ETS2 divergently regulate a cell migration gene
expression program
We previously reported that ETS1 promotes and ETS2 re-
presses migration of DU145 prostate cancer cells (6); how-
ever, it remained unclear if this divergent function was due
to opposite regulation of a common gene expression pro-
gram or via unique target genes. To test if ETS1 and ETS2
regulate a common cell migration gene expression program,
we carried out differential expression analysis by RNA-
sequencing using three biological replicates of DU145 cells
with shRNAs targeting ETS1, ETS2 or luciferase control
(Figure 1A). To examine direct target genes, we only con-
sidered genes with neighboring ETS1 binding sites based on
previous ChIP-seq inDU145 cells (6). Themajority (74.2%)
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Figure 2. Characterization of a functional CRISPR/Cas9 mediated
DU145 ETS1 knockout. (A) Immunoblot of two ETS1 knockout (KO)
lines compared toDU145wild-type (WT) parental. Extended region below
ETS1 band is shown to indicate that no novel spliced or truncated versions
of ETS1 were detected. Size markers in kb on left. Anti-tubulin used as a
loading control. (B) Transwell migration assay demonstrating ETS1 KO
relative to WT as the mean and SEM (n = 3). (C) Chromatin immunopre-
cipitation (ChIP) enrichment for ETS1 by qPCR at known ETS1 binding
sites compared to an unbound control locus. All P-values (* < 0.05, ** <
0.01, *** < 0.001) by t-test as compared to WT.
Figure 3. ETS2 binds to the same sites as ETS1 across the genome. (A)
ETS1, ETS2, JUND and GABPA occupancy near the gene encoding
KIF2C is plotted by -log binomial P-value from ChIP-seq data in DU145
(ETS1, JUND, GABPA) or DU145 ETS1 KO cells (ETS2) and normal-
ized toDU145 genomic input byUSeq (B) Heatmap of enrichment of ETS
factors at all DU145-ETS1 bound regions ranked by difference between in-
tensities of ETS1 and GABPA. Bound region indicated as 5′ to 3′ with an
extended view +/− 7kb in either direction and normalized to DU145 ge-
nomic input by NGSPlot. (C) First and second most enriched motifs in
top 500 or bottom 500 genomic regions shown in (B).
of genes that changed in expression were either activated
by both ETS1 and ETS2, or repressed by both ETS1 and
ETS2, consistent with a common a role for these two pro-
teins at a large portion of the ETS1 cistrome (Figure 1B
and Supplementary Table S4). To investigate why ETS1 and
ETS2 have opposite functions in cell migration we focused
on 337 genes activated by ETS1 (down in ETS1 shRNA)
and repressed by ETS2 (up in ETS2 shRNA). A gene on-
tology search using g:Profiler indicated that the most en-
riched functions of these genes included development, lo-
comotion and cell motility (Figure 1C and Supplementary
Table S5). These categories were not found significantly en-
riched in other quadrants (Supplementary Table S5). These
data indicate that, consistent with the migration phenotype,
ETS1 and ETS2 regulate expression of cell migration genes
in opposite directions.
The transcriptional factor ZEB1 was one of the 337
direct target genes activated by ETS1 and repressed by
ETS2. ZEB1 is known to repress epithelial gene expression
leading to epithelial-mesenchymal transition and increased
cell migration (36). Interestingly, an unbiased search for
over-represented sequence motifs in ETS1-bound regions
near ETS1-repressed genes indicated that ZEB1 binding
sites were the most enriched sequence (Supplemental Fig-
ure S1B). For repressed genes, the ZEB1 binding sequence
was even more enriched than the ETS binding sequence,
whereas the ETS sequence was most enriched near ETS1-
activated genes. These data indicate that, despite nearby
ETS1 binding, that ETS1 mediated repression may occur
via the indirect effect of increased ZEB1 expression.
ETS2 and ETS1 bind the same sites genome-wide
One model that could explain both redundant and opposite
roles for ETS1 and ETS2would be if these proteins compete
for the same cis-regulatory sequences, but vary in their abil-
ity to promote transcription. Therefore, we wanted to test
whether ETS2 binds the ETS1 cistrome.While the ETS1 an-
tibody is specific, all ETS2 antibodies tested also recognized
ETS1 (Supplementary Figure S1C) making it impossible to
verify that an overlapping ChIP signal was coming from
ETS2, and not ETS1 in cells that express both. To over-
come this technical limitation, we created a CRISPR/CAS9
driven ETS1 knockout in DU145 cells using two guide
RNAs in nickase plasmids that target ETS1 exon 3, the first
exon present in all ETS1 isoforms (Supplementary Figure
S2A). After clonal expansion, knockouts were verified by
cloning ETS1 exon 3 into a vector backbone and sequenc-
ing to a depth of n > 5. Two knockout clones were gener-
ated, each with nonsense mutations caused by a common
38 bp duplication in one allele and a unique random inser-
tion of either 10 or 25 bp in the other allele (Supplementary
Figure S2B). Loss of ETS1 protein expression confirmed
the sequencing results (Figure 2A), and loss of cell migra-
tion (Figure 2B) in these strains was consistent with shRNA
knockdowns (6). Further, ETS2 expression did not change
in the two ETS1 knockout clones (Supplementary Figure
S2C). To further verify loss of ETS1, chromatin occupancy
was tested at known ETS1 targeted sites via ChIP quantita-
tive PCR in WT and ETS1 knockout DU145 cell lines. We
observed a significant reduction in ETS1 ChIP signal at all
sites tested in the knockout compared to WT (Figure 2C).
Together these data indicate a functional knockout of ETS1
in DU145 and provides a tool to study the specific roles of
ETS2 throughout the cistrome.
The DU145 ETS1 knockout cell line was then used with
the ETS1/ETS2 dual specificity antibody for ChIP-seq to
determine genome-wide ETS2 binding sites. A subset of
bound regions were validated by ChIP-qPCR (Supplemen-
tary Figure S3A). Of the 1018 ETS2-bound regions iden-
tified by peak calling, 581 (57%) overlapped with regions
bound by ETS1 in WT DU145 cells (Supplementary Fig-
ure S3B). ETS1 and ETS2 had overlapping occupancy at
regulatory sites associated with cell migration genes that
were in the group of 337 activated by ETS1 and repressed
by ETS2, such as KIF2C, ZBTB38, ZEB1 and SLC16A3
(Figure 3A and Supplementary Figure S3C–E). We have
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Figure 4. ETS2 functions as aweak activator compared to ETS1. (A) Tran-
swell migration of DU145 cells expressing FLAG-ETS1 or FLAG-ETS2
are shown relative to DU145 cells with empty vector as a mean and SEM
(n= 3). (B) ZEB1mRNA levels measured byRT-qPCR (normalized to 18s
rRNA) inDU145 cells expressing FLAG-ETS1 or FLAG-ETS2 orDU145
ETS1KO cells compared toDU145 cells with empty vector shown asmean
and SEM (n = 3). (C) Transwell migration of A549 lung cancer cells ex-
pressing ETS1 or ETS2 shRNA shown relative to A549 luciferase shRNA
control as mean and SEM (n = 3). (D) Transwell migration of A549 lung
cancer cells expressing FLAG-ETS2 shown relative to A549 empty control
as mean and SEM (n = 3). (E) Transwell migration of DU145 ETS1 KO
previously shown that ETS1 can bind to two classes of
binding sites; sites bound by many different ETS factors,
which tend to be in the proximal promoters of housekeeping
genes (redundant sites), and sites boundmore specifically by
ETS1, which tend to be in distal enhancers of tissue-specific
genes (specific sites) (37,38). The ETS/AP-1 sequence ele-
ments that regulate expression of cell migration genes tend
to be in specific enhancer sites (6), therefore we hypoth-
esized that, like ETS1, ETS2 might bind both redundant
and ‘ETS1 specific’ sites. Because the ETS factor GABPA
binds almost exclusively to the redundant, promoter sites,
we rank-ordered ETS1-bound regions by GABPA ChIP-
seq signal in DU145 cells to separate redundant and spe-
cific classes (Figure 3B). ETS2-bound regions overlapped
equally with both redundant and specific classes of ETS1
binding sites, indicating overlapping ETS1 and ETS2 bind-
ing across the entire ETS1 cistrome. As a control, we also
compared DU145 ChIP-seq signal for a fourth ETS factor,
ELF1. As expected, ELF1 only overlapped at the redun-
dant (GABPA occupied), but not the specific class of ETS1
sites (Figure 3B). To further characterize regions bound
by ETS1 and ETS2, we determined over-represented se-
quence motifs in the ETS1 and ETS2 ChIP-Seq datasets.
The top 500 (Figure 3B) specific ETS1/2 co-bound regions
were compared to the bottom 500 redundant ETS bound
regions (bound by ETS1, ETS2, GABPA and ELF1) by un-
biased motif search. The specific ETS1/2 co-bound regions
were most enriched for ETS and AP-1 transcription fac-
tor binding sites (Figure 3C). Interestingly, the ETS bind-
ing sequence identified is similar to the GGAA repeat se-
quence bound by EWS-FLI1 in Ewing’s sarcoma (39). Con-
versely, the redundant (bound by all ETS) sites were en-
riched for a consensus ETS sequence and the SP1 sequence
(Figure 3C). JUND, an AP-1 subunit, also had overlapping
binding with ETS1 and ETS2 at key regulatory sites (Fig-
ure 3A and Supplementary Figure S3C–E). We then asked
whether the specific ETS1/2 regions were found proximal
or distal to transcriptional start sites (TSS). 79% of specific
sites were in distal regulatory elements (>300 bp fromTSS),
while 78% of redundant ETS sites were located in proxi-
mal promoter (<300 bp from TSS) neighborhoods (Sup-
plementary Figure S3F). Ontology search algorithms deter-
mined that unique ETS1/2 bound regions were near genes
involved in migration functions such as focal adhesion (P=
5.9 × 10−17) and cell-substrate adherens junction (P = 9.8
× 10−17) (Table 1). Together these data indicate that ETS2,
like most other ETS factors, can bind the consensus ETS
sequences often found in housekeeping gene promoters, but
ETS2 can also bind the ETS/AP-1 sites that are ETS1 tar-
gets in the enhancers of cell migration genes.
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
cells expressing FLAG-ETS1 or FLAG-ETS2 shown relative to DU145
ETS1 KO empty vector as mean and SEM (n = 3). (F) As in (E) but in
second ETS1 KO clone. (G) ZEB1 mRNA levels as in (B), but in DU145
ETS1 KO cells. (H) Relative BCL3 or (I) ZBTB38 mRNA expression in
DU145 ETS1 KO cells as in (G). All P-values (* < 0.05, ** < 0.01, *** <
0.001) by t-test compared to control.
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Table 1. Roles of unique (top 500) versus redundant (bottom 500) ETS1/2 co-bound regions
Category Most over-represented ontologies P-value
Unique, top 500 Focal adhesion 5.9 × 10−17
Cell-substrate adherens junction 9.8 × 10−17
Translational elongation 3.7 × 10−10
Chromatin silencing 1.2 × 10−8
Redundant, bottom 500
RNA processing 7.5 × 10−13
tRNA processing 1.7 × 10−8
Ribosome biogenesis 2.6 × 10−8
rRNA processing 2.8 × 10−4
ETS2 functions as a weak activator in the absence of ETS1
In DU145 prostate cancer cells ETS1 promotes migration
and activation of EMT genes such as Vimentin, while ETS2
has the opposite function (6). Consistent with this, when
over-expressed, ETS2 significantly reduced DU145 cell mi-
gration and reduced expression of the master EMT regula-
tor ZEB1, while ETS1 activated both (Figure 4A and B).
In fact, ETS2 over-expression reduced ZEB1 expression to
a similar extent as the ETS1 knockout (Figure 4B). To test
if this function of ETS2 extends to other cancer cell lines,
ETS2 was knocked down and over-expressed in A549 non-
small cell lung cancer cells and changes in cell migration
were measured (Figure 4C and D). Similar to DU145 cells,
ETS2 acts as a repressor of cell migration and thus oppo-
site to ETS1 in A549 cells. To reduce expression of cell mi-
gration genes, ETS2 could be acting as a transcriptional re-
pressor, or alternatively, ETS2 could simply be a weaker
activator than ETS1, resulting in lower expression when
it displaces ETS1 at cis-acting sequences. To differentiate
between these models, we tested roles of ETS1 and ETS2
in DU145 cells with an ETS1 knockout. In two unique
ETS1 knockout CRISPR clones, expression of exogenous
ETS1 rescued the ∼3-fold reduction in cell migration that
occurred when ETS1 was deleted (Figure 4E and F, com-
pare to Figure 2B). Interestingly, in the ETS1 knockout line,
ETS2 also functioned as an activator of cell migration, al-
beit to a lesser extent than ETS1 (Figure 4E and F). We
also tested expression of a subset of the 337 genes activated
by ETS1 and repressed by ETS2 in WT DU145 cells (Fig-
ure 1B). ZEB1, BCL3 and ZBTB38 expression in DU145
ETS1 knockout cells followed the same trend as the migra-
tion phenotype, with both ETS1 and ETS2 increasing ex-
pression, but ETS1 to a greater extent. (Figure 4G–I). These
data suggest a role for ETS2 that is not repression, but at-
tenuation due a weaker transcriptional activator (ETS2) re-
placing a stronger transcriptional activator (ETS1).
The N-terminal portion of ETS2 is responsible for weaker ac-
tivation than ETS1
To identify the mechanism behind the weaker function of
ETS2 compared to ETS1, we sought to identify the pro-
tein domain responsible. We created ETS1/2 chimeric con-
structs that replaced either the N-terminus, Middle region,
or C-terminus of ETS1 with the corresponding region of
ETS2 (Figure 5A). These ETS1/2 chimeras were transiently
transfected into DU145 prostate cancer cells to similar pro-
tein expression levels (Figure 5B). The transfected cells were
Figure 5. The N-terminal region of ETS2 is sufficient for reduced activa-
tion function compared to ETS1. (A) A schematic of ETS1 and ETS2
showing the two known structured domains; pointed (PNT) and ETS
DNA binding (ETS). Chimeric ETS1/2 constructs are indicated and
named C-N, C-M and C-C for chimera of the N-terminus, middle and C-
terminus, respectively. Darker shaded regions indicate portions stemming
from ETS2, lighter from ETS1. (B) Anti-FLAG immunoblot of DU145
whole cell extract expressing FLAG tagged ETS1, ETS2 and chimeric
constructs with tubulin as a control. (C) Transwell migration of DU145
prostate cancer cells expressing indicated ETS1/2 constructs relative to
empty vector, shown as mean and SEM (n = 3). (D) Relative MEIS2 mes-
senger RNA expression in DU145 cells expressing ETS1/2 constructs nor-
malized to 18S rRNA and relative to empty vector shown as mean and
SEM (n = 3). (E) Relative ZEB1 expression as in (D). All P-values (* <
0.05, ** < 0.01) by t-test compared to empty vector.
then examined to identify which chimeras acted like ETS2
by decreasing cell migration and expression of target genes
such as ZEB1 and MEIS2. Only the chimera consisting of
ETS1with the ETS2N-terminus significantly decreased cell
migration (Figure 5C) and bothMEIS2 and ZEB1 expres-
sion (Figure 5D and E), like ETS2. To further validate the
function of the ETS2 N-terminus, we deleted amino acids
1–68 of ETS2 and found that loss of this region abrogated
the attenuation function of ETS2 over-expressed in A549
cells (Supplementary Figure S4A). These data indicate that
the weaker function of ETS2 compared to ETS1 stems from
the ETS2 N-terminus.
ETS2 specifically recruits the co-repressor ZMYND11 to
ETS1/2 co-bound regions
We postulated that the difference between the N-terminus
of ETS1 and ETS2 is likely a differential interaction with a
co-regulator. The transcriptional co-repressor ZMYND11
(BS69) has been reported to interact with the N-terminus of
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ETS2 (40), but interaction with ETS1 has not been tested.
To compare binding, purified ETS1 and ETS2 were im-
mobilized and used to pull-down proteins from PC3 nu-
clear extract. A ZMYND11 interaction was assayed by
immunoblot. Strikingly, ZMYND11 interacted specifically
with ETS2, and not ETS1 (Figure 6A). A specific interac-
tion that depends on the ETS2N-terminus was further vali-
dated by reverse co-immunoprecipitation of ZMYND11 in
DU145 cells expressing FLAG-ETS1, FLAG-ETS2, or a
FLAG-tagged chimera consisting of ETS1 with the ETS2
N-terminus. Probing the ZMYND11 immunoprecipate
with a FLAG antibody showed that ETS2 and the chimeric
construct, but not ETS1, interacted with ZMYND11 in
cells (Figure 6B). Therefore, the weaker activating function
that can be imparted by the ETS2 N-terminus coincides
with a specific interaction with ZMYND11.
Based on these findings, we proposed a model where
ETS1 and ETS2 compete for the same binding sites, and
when ETS2 is bound it recruits ZMYND11, resulting in re-
duced transcriptional activation. To test this model across
the ETS1/ETS2 cistrome we mapped ZMYND11 binding
by ChIP-seq in both DU145 and ETS1 knockout DU145
cells. ZMYND11 binding was enriched within gene bodies
as previously reported (41), however upon ETS1 deletion,
we observed an increase in ZMYND11 occupancy of pro-
moters and proximal enhancers––regions where ETS1 and
ETS2 often bind (Supplementary Figure S4B). We then fo-
cused directly on the 581 regions bound by ETS1 in DU145
cells and by ETS2 in ETS1 knockout DU145 cells, which we
considered sites of potential ETS1/ETS2 competition. At
these sites, we observed a dramatic induction of ZMYND11
binding when ETS1 was knocked out (Figure 6C and D).
This suggested that ZMYND11 is bound to these regions
more often when ETS2 binding increases due to loss ETS1
competition. As a control, we compared binding in re-
gions where ZMYND11 binds independently of ETS1/2
in both cell lines. These regions had similar ZMYND11
enrichment in both lines (Figure 6D, lower panel), indi-
cating that the observed change in ZMYND11 enrich-
ment is specific to ETS1/ETS2 target sites. Using ChIP-
qPCR we confirmed that ETS1 knockout cells had a signif-
icant increase in ZMYND11 enrichment at known ETS1/2
bound sites near the ZEB1,KIF2C, ZBTB38 and SLC16A3
genes (Figure 6E). Consistent with these findings, 82% of
the 581 ETS1/ETS2-bound regions were co-occupied by
ZMYND11 in ETS1 knockout cells (Supplementary Figure
S3B). Examination of ZMYND11 occupancy at ZBTB38,
KIF2C and ZEB1 enhancers also revealed co-occurrence
with ETS1 and ETS2 binding sites (Figure 6F). Further, we
observed that 53% of the ETS1-bound regions near genes
activated by ETS1 and repressed by ETS2 were co-occupied
by ZMYND11 in the ETS1 knockout line. This was a signif-
icantly higher overlap than at regions near genes repressed
by ETS1 or activated by ETS2 (28-37%) (Supplementary
Figure S4C). This indicates that ZMYND11 binds specifi-
cally to ETS1/2 bound regions near cell migration genes ac-
tivated by ETS1 and repressed by ETS2. These data, taken
together, provide evidence of binding site competition be-
tween ETS1 and an ETS2/ZMYND11 complex, and a po-
tential explanation for opposite roles of ETS1 and ETS2.
ZMYND11 is necessary for repressive functions of ETS2 and
is a tumor suppressor
To test if ZMYND11 is responsible for the opposite role of
ETS2 compared to ETS1, an shRNA was used to knock-
down ZMYND11 expression in DU145 cells (Figure 7A).
Reduced ZMYND11 had little effect on migration of WT
DU145 cells (Figure 7B), possibly because ETS1 is bound to
the ETS/AP-1 regulatory sequences more often than ETS2.
WhenETS2 is over-expressed inDU145 cells to tilt the com-
petitive balance toward ETS2, this resulted in less cell mi-
gration (Figure 3A). Strikingly, when ZMYND11 levels are
reduced, this repressive effect of ETS2 over-expression on
cell migration is eliminated (Figure 7B). Consistent with
this finding, when we knocked down ZMYND11 in ETS1
knockout DU145 cells, where only ETS2 would be occupy-
ing the ETS1/2 specific sites, there was a significant increase
in cell migration (Figure 7C). Interestingly, this boost in mi-
gration (approximately 3-fold) was similar to the extent that
ETS1 rescued migration in the ETS1 knockout (Figure 4E).
This data is consistent with the difference between ETS1
and ETS2 stemming from the ETS2/ZMYND11 interac-
tion.
If ZMYND11 is necessary for ETS2 to act like a tu-
mor suppressor, then differences in ZMYND11 expres-
sion level could explain cell-type specific roles of ETS2 as
a tumor suppressor. To test this, we used TCGA RNA-
sequencing data to rank all epithelial tumor types with
greater than 75 sequenced tumors from lowest to highest
median ZMYND11 expression (Supplementary Figure S5).
The ability of ETS2 to act like a tumor suppressor was then
assessed in each cancer type by comparing outcomes for pa-
tients with tumors where ETS2 expression was higher than
ETS1 versus those where ETS1 expression is higher than
ETS2. In the five cancers with the lowest ZMYND11 levels,
there was no clear benefit to having higher ETS2 than ETS1
(Supplementary Figure S5). However, in the five carcino-
mas with the highest median ZMYND11 expression there
was a trend toward longer recurrence free survival if ETS2
levels were higher than ETS1, and in two of these (non-
small cell lung cancer and prostate adenocarcinoma) this
trend was statistically significant (P < 0.05). This is consis-
tent with previous reports of ETS2 as a tumor suppressor
in both prostate and lung cancer (27,28). Interestingly, HN-
SCC, where ETS2 has been described as an oncogene (19),
had the lowest median levels of ZMYND11 of any tumor
type analyzed (Supplementary Figure S5).
These data suggest that ZMYND11 is a tumor suppres-
sor in prostate and non-small cell lung cancer. To further
explore this hypothesis, we used TCGAdata to test if higher
or lower ZMYND11 expression was associated with recur-
rence free survival. In prostate adenocarcinoma, lower than
median ZMYND11 expression trended toward lower recur-
rence free survival, but this result did not reach statistical
significance (P= 0.0971, Figure 7D). In non-small cell lung
cancers, tumors with lowZMYND11 expression had signif-
icantly lower recurrence free survival (P = 0.00506, Figure
7E). Together these data indicate a role for ZMYND11 to
function in a tumor suppressive manner by allowing ETS2
to attenuate ETS1 function.
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Figure 6. The co-repressor ZMYND11 specifically interacts with ETS2. (A) Anti-ZMYND11 (ZM11) immunoblot of proteins from PC3 nuclear extract
that bind purified ETS1 or ETS2. Ponceau stain of same gel indicates amount of purified protein. (B) Extracts from DU145 cells expressing FLAG-ETS1,
FLAG-ETS2 or FLAG-C-N were co-immunoprecipitated with ZMYND11 antibody and immunoblotted with anti-FLAG. (C) Heatmap of ChIP-seq
enrichment for ZMYND11 within either 581 ETS1/2 co-bound regions, or 174 common ZMYND11 bound regions not bound by ETS1/2 in DU145WT
or DU145 ETS1 KO cell lines. Flanking regions extend ±50 kb, center region spans 500 bp. (D) Average ZMYND11 density profile of same regions from
(C), with ETS1/2 bound regions on top and regions lacking ETS1/2 in lower panel. (E) ChIP-qPCR of ZMYND11 at known ETS1/2 co-bound regions
in DU145 WT versus ETS1 KO cell lines. Data shown as mean and SEM of three biological replicates. All P-values (* < 0.05, ** < 0.01, *** < 0.001, n.s
> 0.05) by t-test. (F) ChIP-seq enrichment of indicated factors across three ETS1/2 bound enhancers.
DISCUSSION
Here we report a specific mechanism that differentiates
the two homologous ETS transcription factors, ETS1 and
ETS2. Due to a specific protein-protein interaction between
the N-terminus of ETS2 and the co-repressor ZMYND11,
ETS1 and ETS2 had different transactivation potential,
resulting in opposite regulation of gene expression when
ETS1 and ETS2 compete for the same binding site. Map-
ping the ETS2 cistrome revealed that these factors do bind
the same genomic regions, and gain of ZMYND11 bind-
ing at these regions in an ETS1 knockout line is consis-
tent with binding site competition. However, at a fraction of
ETS1/2 co-bound sites, ETS2 does appear to compete with
ETS1 without ZMYND11 recruitment, perhaps suggesting
a redundant role at these targets. Interestingly, ZMYND11
levels correlate with the ability of ETS2 to variably act as
either an oncogene or tumor suppressor in epithelial can-
cers. Therefore, these finding suggest a specific mechanism
that establishes an axis that tips the oncogenic function of
the two highly homologous transcription factors, ETS1 and
ETS2.
ETS2 can have distinct functions within different types of
cancer cells. For example, ETS2 functions as an oncogene
in some cancers, such as HNSCC (19), but a tumor sup-
pressor in others, such as prostate (28) and intestine (26).
Our characterization of a role for ZMYND11 in mediat-
ing transcriptional attenuation by ETS2, and the correla-
tion of low ZMYND11 levels in cell types where ETS2 acts
oncogenic, indicates a potential role for ZMYND11 expres-
sion in mediating these distinct functions. It will be inter-
esting to determine if this role for ZMYND11 also regu-
lates other ETS2 functions such as roles in tumor micro-
environment. ETS2 expression in cancer associated fibrob-
lasts and tumor-associated macrophages have been shown
to correlate with poorer outcomes in breast cancers (42–44)
and to promote the ability of colonic stem cells to aber-
rantly divide and colonize into tumors (25). These func-
tions are often the opposite of the role of ETS2 in the tu-
mor cells. These studies highlight the continued dichotomy
in explaining ETS2 function, and the ZMYND11 interac-
tionmay only be onemechanism that determines howETS2
will function in a tumor promoting or inhibiting manner.
Our analysis of TCGA data suggests that ZMYND11
is a tumor suppressor in prostate and lung cancer (Figure
7C and D). This is consistent with a previous report that
ZMYND11 acts as a tumor suppressor in breast cancer
(41). ZMYND11 acts in part, by recruitment of N-CoR
and can repress the function of transcriptional activators,
such as E1A, EBNA-2 and Myb (45,46). Endogenous co-
immunoprecipitation experiments indicate that ETS2 also
interacts with ZMYND11 (40), and our data suggest that
the competition between the ETS2/ ZMYND11 complex
and ETS1 provides a tumor suppressive function to ETS2.
ETS1 and ETS2 are expressed in many malignancies from
leukemias to carcinomas, therefore, ZMYND11 may func-
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tion as a global tumor suppressor that may serve a diagnos-
tic marker for outcomes in a wide variety of cancer types.
ZMYND11 is known to interact with transcription fac-
tors via an MYND domain, which binds a PXLXP motif
present on the interacting factor (45). Interestingly, both
ETS1 and ETS2 have a PXLXP motif in their N-terminus,
however our data indicates that only the N-terminus of
ETS2 can bind ZMYND11 indicating that binding can
be influenced by other sequence differences. Both ETS1
and ETS2 are major downstream nuclear effectors of the
RAS/ERK kinase cascade (9) and we demonstrate that
both ETS1 and ETS2 bind at loci enriched in the RAS-
responsive ETS/AP-1 cis-regulatory element (Figure 3B).
The PXLXP motif on ETS2 (PLLTP) includes the ERK
phosphorylation site T72. It has been reported that ERK
phosphorylation of the T72 residue on ETS2 relieves the
ZMYND11 interaction (40). It is interesting to speculate
whether ZMYND11 binding might also inhibit phosphory-
lation of T72, leading to loss of RAS/ERK responsiveness.
Specific interacting partners that regulate the functions
of ETS1 and ETS2 via the N-terminus, like ZMYND11,
may also be responsible for other divergent functions such
as differences in regulating gene expression leading to B cell
activation into antibody-secreting cells (23). Further, the N-
terminus of ETS1 and ETS2 appears to be a hotspot for
evolutionary divergence of the two genes from a common
Figure 7. ZMYND11 is a putative tumor suppressor. (A) Immunoblot
of DU145 or DU145 ETS1 knockout cells stably expressing ZMYND11
(ZM11) shRNA. Anti-tubulin blot is included as a loading control. (B)
Transwell migration of DU145 cells expressing ZMYND11 shRNA and
over-expression of ETS2 as indicated, shown as mean and SEM (n =
3). (C) Transwell migration of DU145 ETS1 knockout cells expressing
ZMYND11 shRNA or luciferase (luc) shRNA control, shown as mean
and SEM (n = 3). P-value (* < 0.05) by t-test. (D) Kaplan–Meier analysis
of ZMYND11 high versus low RNA expression in TCGA prostate ade-
nocarcinoma data. P-value calculated via Chi-square test with one degree
of freedom. (E) Kaplan–Meier analysis as in (D) for non-small cell lung
cancer.
ancestor. In chickens, an extended N-terminal ETS1 (p68)
isoform is expressed, and the p68 ETS1 N-terminus has a
similar function to the ETS2 N-terminus (47). Whether this
function is related to ZMYND11 binding is unknown.
Recently it has been discovered that ZMYND11 func-
tions as a reader of the Lysine 36 trimethylation (K36me3)
mark on the histone variant H3.3 (41). The deposition
of K36me3 occurs in the gene bodies, and subsequent re-
cruitment of ZMYND11 to gene bodies leads to changes
in transcriptional elongation and splicing (41,48). Inter-
estingly, the most enriched KEGG pathway upregulated
by ZMYND11 knockdown cells in a previous report (41)
was ‘Focal adhesion’, which matches our pathway most en-
riched in genes bound specifically by ETS1 and ETS2 (Table
1). Therefore, it seems possible that ETS2 plays a key role
in the recruitment of ZMYND11 to these tumor suppressor
genes.
Taken together, our findings indicate a novel mechanism
responsible for the divergent oncogenic phenotypes medi-
ated by ETS1 and ETS2 in epithelial cancers and point the
way for treatment options that could increase the function
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